Literature DB >> 19223692

Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition.

Chaoshi Niu1, Jiaming Mei, Qi Pan, Xianming Fu.   

Abstract

OBJECTIVE: We were interested in studying nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition.
METHODS: Observation of progressive behavioral and pathological changes in rats following a unilateral nigral injection of lactacystin, a selective proteasome inhibitor.
RESULTS: After administration at a concentration of 10 microg (2 microl) of lactacystin, when tyrosine hydroxylase (TH) immunostaining decreased gradually in the substantia nigra pars compacta (SNc) and corpus striatum, alpha-synuclein-immunopositive inclusion appeared extensively in the surviving neurons. We also observed the degeneration of diverse cellular organelles by transmission electron microscopy. The effect of cellular organelle degeneration on behavior, a clinical index, was striking and was statistically significant. Over the 3 weeks following the administration of lactacystin, a highly significant decrease in TH immunostaining was observed and alpha-synuclein-immunopositive inclusions gradually appeared. Interestingly, there was a strong correlation in behavioral changes and the increase in alpha-synuclein-immunopositive inclusions whereas the decrease in TH immunostaining did not seem to induce any behavioral changes.
CONCLUSIONS: Our results reveal that unilateral nigral proteasome inhibition induces degeneration in the SNc and corpus striatum as well as behavioral changes demonstrating strong time dependence. Behavioral changes were driven by the formation of alpha-synuclein inclusions, but not by decreased TH neurons. (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19223692      PMCID: PMC2790800          DOI: 10.1159/000202972

Source DB:  PubMed          Journal:  Stereotact Funct Neurosurg        ISSN: 1011-6125            Impact factor:   1.875


  38 in total

1.  Proteasomal function is impaired in substantia nigra in Parkinson's disease.

Authors:  K S McNaught; P Jenner
Journal:  Neurosci Lett       Date:  2001-01-19       Impact factor: 3.046

2.  Early behavioral changes after nigro-striatal system damage can serve as predictors of striatal dopamine depletion.

Authors:  J Fornaguera; R K Schwarting
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1999-11       Impact factor: 5.067

3.  Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells.

Authors:  H J Rideout; K E Larsen; D Sulzer; L Stefanis
Journal:  J Neurochem       Date:  2001-08       Impact factor: 5.372

4.  Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.

Authors:  Pavan K Auluck; H Y Edwin Chan; John Q Trojanowski; Virginia M Y Lee; Nancy M Bonini
Journal:  Science       Date:  2001-12-20       Impact factor: 47.728

5.  Differential effects of a small, unilateral, 6-hydroxydopamine-induced nigral lesion on behavior in high and low responders to novelty.

Authors:  R V van Oosten; A R Cools
Journal:  Exp Neurol       Date:  2002-02       Impact factor: 5.330

6.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease.

Authors:  R Betarbet; T B Sherer; G MacKenzie; M Garcia-Osuna; A V Panov; J T Greenamyre
Journal:  Nat Neurosci       Date:  2000-12       Impact factor: 24.884

7.  SPECT imaging, immunohistochemical and behavioural correlations in the primate models of Parkinson's disease.

Authors:  Keyoumars Ashkan; Bradley A Wallace; John Mitrofanis; Claudio Pollo; Pierre-Yves Brard; Daniel Fagret; Alim-Louis Benabid
Journal:  Parkinsonism Relat Disord       Date:  2006-12-29       Impact factor: 4.891

8.  Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.

Authors:  M Lundblad; M Andersson; C Winkler; D Kirik; N Wierup; M Angela Cenci
Journal:  Eur J Neurosci       Date:  2002-01       Impact factor: 3.386

9.  Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.

Authors:  Michael K Lee; Wanda Stirling; Yanqun Xu; Xueying Xu; Dike Qui; Allen S Mandir; Ted M Dawson; Neal G Copeland; Nancy A Jenkins; Don L Price
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

10.  Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures.

Authors:  Kevin St P McNaught; Catherine Mytilineou; Ruth Jnobaptiste; Jocelyn Yabut; P Shashidharan; Peter Jennert; C Warren Olanow
Journal:  J Neurochem       Date:  2002-04       Impact factor: 5.372

View more
  14 in total

1.  Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.

Authors:  Ian F Harrison; William R Crum; Anthony C Vernon; David T Dexter
Journal:  Br J Pharmacol       Date:  2015-07-08       Impact factor: 8.739

2.  Effects of CDNF on 6-OHDA-induced apoptosis in PC12 cells via modulation of Bcl-2/Bax and caspase-3 activation.

Authors:  Jia-Ming Mei; Chao-Shi Niu
Journal:  Neurol Sci       Date:  2014-03-15       Impact factor: 3.307

3.  Morphological and metabolic changes in the nigro-striatal pathway of synthetic proteasome inhibitor (PSI)-treated rats: a MRI and MRS study.

Authors:  Stefano Delli Pizzi; Cosmo Rossi; Vincenzo Di Matteo; Ennio Esposito; Simone Guarnieri; Maria Addolorata Mariggiò; Raffaella Franciotti; Massimo Caulo; Astrid Thomas; Marco Onofrj; Armando Tartaro; Laura Bonanni
Journal:  PLoS One       Date:  2013-02-19       Impact factor: 3.240

4.  Impaired voluntary wheel running behavior in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.

Authors:  Qi Pan; Wangming Zhang; Jinyan Wang; Fei Luo; Jingyu Chang; Ruxiang Xu
Journal:  J Korean Neurosurg Soc       Date:  2015-02-26

5.  Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease.

Authors:  Jolanta Konieczny; Danuta Jantas; Tomasz Lenda; Helena Domin; Anna Czarnecka; Katarzyna Kuter; Maria Śmiałowska; Władysław Lasoń; Elżbieta Lorenc-Koci
Journal:  Neurotox Res       Date:  2014-05-20       Impact factor: 3.911

Review 6.  The Proteasome Inhibition Model of Parkinson's Disease.

Authors:  Eduard Bentea; Lise Verbruggen; Ann Massie
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

7.  The analysis of differential induction of hsp70 in the related cerebral domains and nerve fibers of rats after proteasome inhibiton.

Authors:  Jia-Ming Mei; Chao-Shi Niu; Xiao-Rui Fei
Journal:  Ann Neurosci       Date:  2011-04

8.  Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate.

Authors:  Ian F Harrison; Hiba K Anis; David T Dexter
Journal:  Neurosci Lett       Date:  2015-12-29       Impact factor: 3.046

9.  Repetitive transcranial magnetic stimulation for treatment of lactacystin-induced Parkinsonian rat model.

Authors:  Maowen Ba; Guozhao Ma; Chao Ren; Xuwen Sun; Min Kong
Journal:  Oncotarget       Date:  2017-04-20

10.  How does conserved dopamine neurotrophic factor protect against and rescue neurodegeneration of PC12 cells?

Authors:  Jia-Ming Mei; Chao-Shi Niu
Journal:  Neural Regen Res       Date:  2017-07       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.